H
Hans R. Brunner
Researcher at University of Lausanne
Publications - 327
Citations - 21494
Hans R. Brunner is an academic researcher from University of Lausanne. The author has contributed to research in topics: Blood pressure & Angiotensin II. The author has an hindex of 67, co-authored 325 publications receiving 21070 citations. Previous affiliations of Hans R. Brunner include Boston University & École Polytechnique Fédérale de Lausanne.
Papers
More filters
Journal ArticleDOI
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
Stevo Julius,Sverre E. Kjeldsen,Michael A. Weber,Hans R. Brunner,Steffan Ekman,Lennart Hansson,Tsushung Hua,John H. Laragh,Gordon T. McInnes,Lada Mitchell,Francis Plat,Anthony Schork,Beverly Smith,Alberto Zanchetti +13 more
TL;DR: Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period, which emphasise the importance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.
Journal ArticleDOI
Essential hypertension: renin and aldosterone, heart attack and stroke
Hans R. Brunner,John H. Laragh,Leslie Baer,Michael A. Newton,Frank T. Goodwin,Lawrence R. Krakoff,Richard H. Bard,Fritz R. Bühler +7 more
TL;DR: Plasma renin activity emerges as a potential risk factor for patients with essential hypertension — useful for identifying etiologies, determining prognosis and applying therapy.
Journal ArticleDOI
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.
TL;DR: The drug was uniformly effective in 13 patients with high renin activity and malignant, renovascular, or essential hypertension, producing a mean fall in diastolic pressure of 30 mm of mercury, but individual responses were less consistent.
Journal ArticleDOI
Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man
Haralambos Gavras,Hans R. Brunner,Gustave A. Turini,Glenn R. Kershaw,Charles P. Tifft,Sergio Cuttelod,Irene Gavras,Robert A. Vukovich,Doris N. McKinstry +8 more
TL;DR: SQ 14225 is a promising new antihypertensive agent, effective in patients refractory to traditional medical therapy, and the exact mechanisms contributing to the blood-pressure-lowering effect of this agent remain unclear.
Journal ArticleDOI
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
Michael A. Weber,Stevo Julius,Sverre E. Kjeldsen,Hans R. Brunner,Steffan Ekman,Lennart Hansson,Tsushung Hua,John H. Laragh,Gordon T. McInnes,Lada Mitchell,Francis Plat,M. Anthony Schork,Beverly Smith,Alberto Zanchetti +13 more
TL;DR: Reaching blood pressure control by 6 months, independent of drug type, was associated with significant benefits for subsequent major outcomes; the blood pressure response after just 1 month of treatment predicted events and survival.